Jury Sides with Endo in Antitrust Action Alleging Illegal Pay-for-Delay Deal
- July 08, 2022
Purchasers of Endo Pharmaceutical Inc.’s extended-release opioid, Opana ER, lost their antitrust action against the company alleging it entered into an illegal pay-for-delay delay to block generic entry of the drug.
ARTICLE TAGS
You must be logged in to access this content.